These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3503035)

  • 21. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the efficacy of the treatment of Raynaud's phenomenon with nifedipine by laser-Doppler flowmetry.
    Belcaro GV; Gabini M; Cacchio M
    Panminerva Med; 1987; 29(3):223-7. PubMed ID: 2962057
    [No Abstract]   [Full Text] [Related]  

  • 23. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.
    Ettinger WH; Wise RA; Schaffhauser D; Wigley FM
    Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.
    Antcliff AC; Bouhoutsos J; Martin P; Morris T
    Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806
    [No Abstract]   [Full Text] [Related]  

  • 25. [Comparative study of misoprostol and nifedipine in the treatment of Raynaud's phenomenon secondary to systemic diseases. Hemodynamic assessment with Doppler duplex].
    Varela-Aguilar JM; Sánchez-Román J; Talegón Meléndez A; Castillo Palma MJ
    Rev Clin Esp; 1997 Feb; 197(2):77-83. PubMed ID: 9213861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon.
    Khan F; Coffman JD
    Circulation; 1994 Mar; 89(3):1183-8. PubMed ID: 8124805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topical nitroglycerin ointment in Raynaud's phenomenon.
    Fischer M; Reinhold B; Falck H; Török M; Alexander K
    Z Kardiol; 1985 May; 74(5):298-302. PubMed ID: 3925656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
    Dormandy JA; Berent A; Downes SJ
    Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Digital blood flow in cooled and contralateral finger in patients with Raynaud's phenomenon. Comparative measurements between photoelectrical plethysmography and laser Doppler flowmetry.
    Suichies HE; Aarnoudse JG; Wouda AA; Jentink HW; de Mul FF; Greve J
    Angiology; 1992 Feb; 43(2):134-41. PubMed ID: 1536474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud's phenomenon.
    Engelhart M; Seibold JR
    Angiology; 1990 Sep; 41(9 Pt 1):715-23. PubMed ID: 2221472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raynaud's phenomenon. Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up.
    Wouda AA
    Acta Med Scand; 1977; 201(6):519-23. PubMed ID: 878907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon.
    Belch JJ; Madhok R; Shaw B; Leiberman P; Sturrock RD; Forbes CD
    Lancet; 1985 May; 1(8439):1180-3. PubMed ID: 2860386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nifedipine in the treatment of Raynaud's syndrome.
    Aldoori M; Campbell WB; Dieppe PA
    Cardiovasc Res; 1986 Jun; 20(6):466-70. PubMed ID: 3536108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The influence of isosorbide mononitrate on skin blood flow in patients with Raynaud's syndrome].
    Gross R; Galus K; Zajac S; Jedrasik M
    Wiad Lek; 2002; 55(1-2):29-34. PubMed ID: 12043312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon.
    Kahan A; Foult JM; Weber S; Amor B; Menkes CJ; Degeorges M
    Eur Heart J; 1985 Aug; 6(8):702-5. PubMed ID: 4054140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.